Tr1x

San Diego, United States

Tr1x is a biotechnology company developing novel cellular immunotherapies for patients with autoimmune and inflammatory diseases.

$50.0M raised

Oct 2025

Venture - Series Unknown

Top Investors

The Column GroupNeva SGRAlexandria Venture InvestmentsCalifornia Institute for Regenerative Medicine

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Tr1x raised?

Tr1x has raised $50.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in October 2025.

Who are Tr1x's investors?

Tr1x's investors include The Column Group, Neva SGR, Alexandria Venture Investments, California Institute for Regenerative Medicine.

Where is Tr1x headquartered?

Tr1x is headquartered in San Diego, United States.

What does Tr1x do?

Tr1x is a biotechnology company developing novel cellular immunotherapies for patients with autoimmune and inflammatory diseases.

What stage is Tr1x at?

Tr1x is at the Venture - Series Unknown stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated October 14, 2025.

MLA

"Tr1x — Funding & Investors." VCBacked, October 14, 2025, https://www.vcbacked.co/company/tr1x. Accessed June 30, 2026.

APA

VCBacked. (2025). Tr1x — Funding & Investors. Retrieved June 30, 2026, from https://www.vcbacked.co/company/tr1x

Wikipedia (cite web)

{{cite web |title=Tr1x — Funding & Investors |url=https://www.vcbacked.co/company/tr1x |website=VCBacked |access-date=June 30, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated October 14, 2025.